Back to Stakeholders

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.

Academic Research

0 papers

Published Papers

0

Trial Involvement

8

Distinct Focus Topics

0

Latest Publication

Unknown

Entity type: Research Centre / Institute

Network Scope

Hospital-network model with affiliated research institutes and multi-program collaborations.

Connected Research Organizations

Collaboration Notes

Large academic health network with university-linked research programs, including psychiatric and translational collaborations.

Collaboration Info

Clinical Care Delivery Snapshot

Health Systems & Hospitals

Provider Model

Health System / Hospital Program

Organization Status

Unknown

Psychedelic Services

Unknown

Service Coverage

Global

Service Profile

Care Settings

Hospital Outpatient

Payer Models

Unknown

Non-Psychedelic Service Mix

Unknown

Visit Provider

Care Delivery Notes

Backfilled profile for existing L2 clinical care delivery stakeholder.

Quick Facts

Type
Other
HQ
Canada
Website
Visit

Sponsored Trials

7

Collaborated Trials

1